Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines - PubMed (original) (raw)
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
B Fisk et al. J Exp Med. 1995.
Abstract
Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance to tumor, and structural characterization of tumor antigens.
Similar articles
- HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M. Baxevanis CN, et al. Int J Cancer. 2002 Apr 20;98(6):864-72. doi: 10.1002/ijc.10251. Int J Cancer. 2002. PMID: 11948464 - Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.
Castilleja A, Ward NE, O'Brian CA, Swearingen B 2nd, Swan E, Gillogly MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG. Castilleja A, et al. Mol Cell Biochem. 2001 Jan;217(1-2):21-33. doi: 10.1023/a:1007267814251. Mol Cell Biochem. 2001. PMID: 11269662 - Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 2006 Jan;55(1):85-95. doi: 10.1007/s00262-005-0692-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15948002 Free PMC article. Review. - Immunity to the HER-2/neu oncogenic protein.
Disis ML, Bernhard H, Gralow JR, Hand SL, Emery SR, Calenoff E, Cheever MA. Disis ML, et al. Ciba Found Symp. 1994;187:198-207; discussion 207-11. doi: 10.1002/9780470514672.ch13. Ciba Found Symp. 1994. PMID: 7540970 Review.
Cited by
- Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Goldberg J, et al. Cancer Res Commun. 2024 Feb 22;4(2):496-504. doi: 10.1158/2767-9764.CRC-23-0244. Cancer Res Commun. 2024. PMID: 38335301 Free PMC article. - Comparison of Anti-Trop2 Extracellular Domain Antibodies Generated Against Peptide and Protein Immunogens for Targeting Trop2-Positive Tumour Cells.
Kamble PR, Kulkarni B, Malaviya A, Bajaj M, Breed AA, Jagtap D, Mahale S, Pathak BR. Kamble PR, et al. Appl Biochem Biotechnol. 2024 Jun;196(6):3402-3419. doi: 10.1007/s12010-023-04706-4. Epub 2023 Sep 1. Appl Biochem Biotechnol. 2024. PMID: 37656352 - Creation and characterization of a recombinant mammalian orthoreovirus expressing σ1 fusion proteins encoding human epidermal growth factor receptor 2 peptides.
Jandick NA, Miller CL. Jandick NA, et al. Virology. 2023 Oct;587:109871. doi: 10.1016/j.virol.2023.109871. Epub 2023 Aug 19. Virology. 2023. PMID: 37634292 Free PMC article. - Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.
Nhàn NTT, Yamada T, Yamada KH. Nhàn NTT, et al. Int J Mol Sci. 2023 Aug 18;24(16):12931. doi: 10.3390/ijms241612931. Int J Mol Sci. 2023. PMID: 37629112 Free PMC article. Review. - The landscape of T cell antigens for cancer immunotherapy.
Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. Peri A, et al. Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6. Nat Cancer. 2023. PMID: 37415076 Review.
References
- Nature. 1986 Jan 16-22;319(6050):230-4 - PubMed
- Lymphokine Cytokine Res. 1994 Apr;13(2):125-31 - PubMed
- J Exp Med. 1988 Aug 1;168(2):725-36 - PubMed
- J Biol Chem. 1988 Sep 15;263(26):12820-3 - PubMed
- Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous